Centene raises 2026 adjusted EPS outlook to above $4.80 as medical costs ease
AI Market Summary
Centene’s Q2 results showed sharply improved medical cost performance, with medical loss ratio at 89.6% versus 93% last year and below consensus. Management raised 2026 adjusted EPS guidance to above $4.80 and lifted full-year revenue guidance, signaling better pricing and favorable risk-adjustment dynamics despite broader ACA enrollment pressure. The beat and higher outlook should support health insurer sentiment and reduce near-term profitability concerns in the sector.
Impact level
● Medium
Affected assets
NCSKMS2USD/USDT-3.99%
AI Insight · NCSKMS2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Centene reported second-quarter results showing its medical loss ratio fell to 89.6%, down from 93% a year earlier and below analysts’ 91.30% estimate. The company raised its 2026 adjusted earnings-per-share forecast to more than $4.80 from above $3.40. It also lifted its full-year revenue outlook to $193.5 billion–$197.5 billion. The improved cost performance pushed Centene shares up more than 2% in premarket trading.
